Keywords: early, use, merck, co, aggrastat, benefits, stemi
Early use of Merck & Co's Aggrastat benefits STEMI patients
Article | 08 September 2008
Early, in-ambulance treatment with antiplatelet agent, US drug major Merck & Co's Aggrastat (tirofiban HCl), in addition to the standard combined ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
